BFO
AZN icon

Biltmore Family Office’s AstraZeneca AZN Stock Holding History

Biltmore Family Office’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,478
Closed -$230K – 268
2024
Q3 		$230K Buy
+1,478
New +$239K 0.04% 191

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Biltmore Family Office's AZN Position: Q4 2024 in Review

Biltmore Family Office sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 1,478 shares — an estimated $230K sold.

Biltmore Family Office first reported a position in AZN in Q3 2024 and held it in 1 quarter. The position peaked at $230K in Q3 2024. 1,218 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Biltmore Family Office reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
  • Biltmore Family Office sold 1,478 AstraZeneca shares in Q4 2024, an estimated $230K.
  • Biltmore Family Office first reported a position in AstraZeneca in Q3 2024 and held it in 1 quarter.
  • Biltmore Family Office's AstraZeneca position peaked at $230K in Q3 2024.
  • 1,218 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Biltmore Family Office's 13F filing for Q4 2024, filed 12 Feb 2025.